The company announced that by an unanimous vote, the FDA’s Oncologic Drugs Advisory Committee said the agency should not approve GPC’s satraplatin before seeing final survival results from a late stage trial. GPC Biotech said it would not be able to provide that data until late 2008, according to Reuters.
Last year, the company lost over $87 million on revenue of less than $30 million. Even with its shares down this much, it still sports a market cap of almost $500 million.
What a peach.
Douglas A. McIntyre